MERCK & CO. INC. (MRK) Stock Price, Forecast & Analysis
NYSE:MRK • US58933Y1055
MRK Key Statistics, Chart & Performance
The current stock price of MRK is 122.26 USD. In the past month the price increased by 11.98%. In the past year, price increased by 36.6%.
MRK Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to MRK. When comparing the yearly performance of all stocks, MRK is one of the better performing stocks in the market, outperforming 84.89% of all stocks.
MRK Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to MRK. While MRK has a great profitability rating, there are some minor concerns on its financial health.
MRK Financial Highlights
Over the last trailing twelve months MRK reported a non-GAAP Earnings per Share(EPS) of 9.18. The EPS increased by 20.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 29.63% | ||
| ROA | 14.69% | ||
| ROE | 36.71% | ||
| Debt/Equity | 0.77 |
MRK Forecast & Estimates
34 analysts have analysed MRK and the average price target is 118.61 USD. This implies a price decrease of -2.99% is expected in the next year compared to the current price of 122.26.
For the next year, analysts expect an EPS growth of -41.06% and a revenue growth 4.34% for MRK
MRK Ownership
MRK Latest News, Press Relases and Analysis
MRK Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.08 | 967.332B | ||
| JNJ | JOHNSON & JOHNSON | 20.81 | 594.88B | ||
| PFE | PFIZER INC | 8.87 | 152.718B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.97 | 122.756B | ||
| ZTS | ZOETIS INC | 18.75 | 56.091B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.7 | 26.039B | ||
| VTRS | VIATRIS INC | 6.29 | 18.405B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.89 | 12.521B | ||
| AXSM | AXSOME THERAPEUTICS INC | 224.33 | 9.385B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MRK
Company Profile
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company is headquartered in Rahway, New Jersey. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The firm sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
Company Info
MERCK & CO. INC.
126 East Lincoln Avenue, P.O. Box 2000
Rahway NEW JERSEY 07033 US
CEO: Kenneth C. Frazier
Employees: 75000
Phone: 19087404000
MERCK & CO. INC. / MRK FAQ
What does MRK do?
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company is headquartered in Rahway, New Jersey. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The firm sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
Can you provide the latest stock price for MERCK & CO. INC.?
The current stock price of MRK is 122.26 USD. The price increased by 0.33% in the last trading session.
What is the dividend status of MERCK & CO. INC.?
MERCK & CO. INC. (MRK) has a dividend yield of 2.79%. The yearly dividend amount is currently 3.1.
How is the ChartMill rating for MERCK & CO. INC.?
MRK has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What is the analyst forecast for MRK stock?
34 analysts have analysed MRK and the average price target is 118.61 USD. This implies a price decrease of -2.99% is expected in the next year compared to the current price of 122.26.
How many employees does MERCK & CO. INC. have?
MERCK & CO. INC. (MRK) currently has 75000 employees.
What is the next earnings date for MRK stock?
MERCK & CO. INC. (MRK) will report earnings on 2026-04-30.